[{"id":"456fe0b1-e282-4742-af6a-8e9793d91f27","acronym":"","url":"https://clinicaltrials.gov/study/NCT00824135","created_at":"2021-01-18T03:08:02.831Z","updated_at":"2024-07-02T16:37:26.788Z","phase":"Phase 1","brief_title":"Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies","source_id_and_acronym":"NCT00824135","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • clofarabine • melphalan • thiotepa • Orthoclone OKT3 (muromonab-CD3)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-02"}]